Gilead Sciences, Inc. vs Williams Companies Inc — how do they compare? Gilead Sciences, Inc. trades at $135.68 (market cap $168.35B), while Williams Companies Inc trades at $73.13 (market cap $88.45B). The key difference: Gilead Sciences, Inc. is the larger of the two by market cap, and Williams Companies Inc pays the higher dividend (2.9%). Which is the better fit depends on your goals.
| GILD | WMB | |
|---|---|---|
Market Cap | $168.35B | $88.45B |
Sector | Health | Energy |
52-Week High | $155.80 | $79.40 |
52-Week Low | $110.56 | $56.51 |
Enterprise Value | $191.42B | $119.07B |
Dividend Yield | 2.42% | 2.9% |
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.06, down slightly by 0.11% today, with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 revenue growth of 8% year-over-year, beating estimates, though a net loss of $6.75 per share resulted from acquisition-related costs. Analyst consensus is strongly bullish with a $151.22 price target, and recent news highlights robust HIV drug sales and pipeline progress.
The outlook for GILD is positive, driven by raised 2026 guidance and HIV franchise strength, but risks include patent cliffs by the mid-2030s and integration challenges from acquisitions. Investors should weigh the high valuation multiples against growth potential, with the stock offering upside if execution continues to exceed expectations.
Williams Companies (WMB) trades at $71.85, up 2.06% today, with a neutral technical signal and mixed earnings history. The company reported Q2 2026 EPS of $0.50, slightly missing estimates, but raised full-year EBITDA guidance. Recent news highlights the $5.5 billion acquisition of Momentum Midstream, enhancing its Gulf Coast presence and supporting long-term growth targets. Financials show strong profitability with a 25.18% net income margin and robust cash flow from operations of $5.90 billion in 2025.
Outlook remains positive with analyst consensus favoring Buy ratings (79.41%) and a $87.14 price target, though risks include execution of acquisitions and debt levels. The stock offers a dividend yield supported by stable cash flows, positioning it for growth in energy infrastructure demand.
Trailing returns across standard periods
Latest headlines on both assets
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →Williams is a midstream energy company that owns and operates the large Transco and Northwest pipeline systems and associated natural gas gathering, processing, and storage assets. In August 2018, the firm acquired the remaining 26% ownership of its limited partner, Williams Partners.
Read more on WMB →